LGD-4033 vs Turinabol
Moderate Research vs Moderate Research
avoid Mechanism-based · 64% Both LGD-4033 and Turinabol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
LGD-4033 Turinabol
Weight 338.25 Da 334.88 Da
Half-life ~24-36 hours ~16 hours
Type Nonsteroidal selective androgen receptor modulator (C14H12F6N2O) 17-alpha-alkylated anabolic-androgenic steroid (C20H27ClO2)
Key Benefits
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Turinabol
01 Promotes lean, dry muscle gains without water retention or bloating
02 Does not aromatize to estrogen, eliminating risk of gynecomastia and estrogen-related side effects
03 Favorable anabolic-to-androgenic ratio, reducing androgenic side effects relative to muscle-building potential
04 Enhances muscular endurance and recovery through increased red blood cell production
05 Increases strength without significant body weight gain, beneficial for weight-class athletes
06 Improves creatine phosphate resynthesis, supporting repeated high-intensity efforts
07 Relatively mild androgenic profile compared to most oral anabolic steroids
08 Produces slow, steady, maintainable gains rather than rapid temporary increases
Side Effects
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Turinabol
Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent
HDL cholesterol suppression (significant, often 30-50% reduction)
LDL cholesterol elevation
Suppression of endogenous testosterone production via HPG axis negative feedback
Mild gastrointestinal discomfort or nausea
Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds)
Oily skin and mild acne
Decreased appetite in some users
Contraindications
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Known or suspected prostate cancer
Breast cancer in males
Pregnancy or planned pregnancy (teratogenic risk)
Active liver disease or significant hepatic impairment
Pre-existing severe dyslipidemia or cardiovascular disease
Hypersensitivity to turinabol or related compounds
Research Evidence
LGD-4033 Turinabol
Status Moderate Research Moderate Research
References 5 studies 5 studies
Latest 2018 June 2023
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.